Chronic hepatitis C (HCV) infection remains a major public health problem with many infected individuals worldwide. The revolutionary discovery of highly effective direct-acting antivirals (DAAs) makes chronic HCV infection a curable disease, even in patients with advanced liver disease. Liver function may improve shortly after initiation of antiviral therapy in patients on the waiting list and could even obviate the need for transplantation. However, whether these short term benefits also result in a favorable prognosis on the long-term remains to be seen and this fuels the discussion whether DAAs should be used prior to liver transplantation in all patients. Following liver transplantation, DAA treatment is also highly effective so that postponing antiviral treatment to the post-transplant setting may be better for certain patients. Furthermore, the discussion whether HCV positive organ donors should be used now viral eradication is achieved in almost all patients has regained interest.

Additional Metadata
Keywords Chronic hepatitis C, DAA therapy, HCV positive donors, HCV recurrence, Liver transplantation
Persistent URL dx.doi.org/10.1016/j.bpg.2017.04.006, hdl.handle.net/1765/108561
Journal Best Practice and Research in Clinical Gastroenterology
Citation
van Tilborg, M, Maan, R, van der Meer, A.J.P, & de Knegt, R.J. (2017). Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Practice and Research in Clinical Gastroenterology (Vol. 31, pp. 219–225). doi:10.1016/j.bpg.2017.04.006